secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001628280-22-014491
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical Q1 net loss $7.2M, DaVita invests $7.5M and amends supply deal
-------------------------------------------------------------------------------

- Q1 net sales $16.1M (+4.2% YoY); gross loss $0.8M vs. gross profit $0.4M last year due to inflation.
- Net loss $7.2M ($0.84/sh) compared to $7.8M ($0.91/sh) in Q1 2021; cash $9.9M at March 31.
- DaVita amended supply agreement with price increases and cost pass-through; invested $7.5M in convertible preferred stock, with potential additional $7.5M.
- Submitted supplemental data to FDA for IND to enable Phase 2 FPC home infusion trial; awaiting 30-day review.
- Partner Wanbang completed Phase 3 Triferic Dialysate enrollment in China; NDA submission targeted Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000162828022014491/0001628280-22-014491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000162828022014491/rmti-20220516.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-014491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer